We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease.
- Authors
Welge, Volker; Fiege, Oliver; Lewczuk, Piotr; Mollenhauer, Brit; Esselmann, Hermann; Klafki, Hans-Wolfgang; Wolf, Stefanie; Trenkwalder, Claudia; Otto, Markus; Kornhuber, Johannes; Wiltfang, Jens; Bibl, Mirko
- Abstract
Cerebrospinal fluid (CSF) concentrations of amyloid-beta (Abeta) 1-38, 1-40, 1-42, total-tau and phospho-tau in samples from 156 patients with Alzheimer's disease (AD) (n = 44), depressive cognitive complainers (DCC, n = 25) and various other forms of non-Alzheimer dementias (NAD, n = 87) were analyzed by electrochemiluminescence and enzyme linked immunosorbent assay, respectively. A significant decrease of CSF Abeta1-42 was the most powerful single marker for differentiation of AD from DCC, yielding accuracies of beyond 85%. Increased p-tau and the ratio Abeta1-42/Abeta1-38 yielded accuracies of beyond 80 and 85%, respectively, to discriminate AD versus NAD. Combining p-tau with Abeta1-42/Abeta1-38 resulted in a sensitivity of 94% for detection of AD and 85% specificity for excluding NAD. Decreased CSF Abeta1-42 represents a core biomarker for AD. The lack of specificity for exclusion of NAD can be most effectively compensated by the ratio Abeta1-42/Abeta1-38. The ratio Abeta1-42/Abeta1-38/p-tau powerfully discriminates AD versus NAD and fulfils the accuracy requirements for an applicable screening and differential diagnostic AD biomarker.
- Publication
Journal of neural transmission (Vienna, Austria : 1996), 2009, Vol 116, Issue 2, p203
- ISSN
0300-9564
- Publication type
Journal Article
- DOI
10.1007/s00702-008-0177-6